Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients

Clinical Radiology

Volumn 65, Issue 4, 2010, Pages 271-277

  Yoon, H J ^a   Kim, J H ^a   Kim, K A ^a   Lee, I S ^a   Ko, G Y ^a   Song, H Y ^a   Gwon, D I ^a  

^a Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CISPLATIN; IODINATED POPPYSEED OIL; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BILE DUCT DILATATION; BILIRUBIN BLOOD LEVEL; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEPATIC ARTERY; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TRANSCATHETER ARTERIAL CHEMO LIPIODOL INFUSION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77949560111     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2010.01.018     Document Type: Article

References (30)

1. Takayasu K., Arii S., Ikai I., et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131 (2006) 461-469
2. Bosch F.X., Ribes J., Díaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-16
3. Shen H., Agarwal D., Qi R., et al. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther 26 (2007) 393-400
4. Chung Y.H., Song I.H., Song B.C., et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88 (2000) 1986-1991
5. Brown D.B., Cardella J.F., Sacks D., et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 17 (2006) 225-232
6. Llovet J.M., Real M.I., Montaña X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
7. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
8. Chung J.W., Park J.H., Han J.K., et al. Hepatic tumours: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198 (1996) 33-40
9. Savastano S., Miotto D., Casarrubea G., et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 28 (1999) 334-340
10. Kiely J.M., Rilling W.S., Touzios J.G., et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol 17 (2006) 47-53
11. Kothary N., Weintraub J.L., Susman J., et al. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 18 (2007) 1517-1527
12. Maeda S., Fujiyama S., Tanaka M., et al. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res. 23 (2002) 202-210
13. Ahn S.H., Han K.H., Park J.Y., et al. Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa). Yonsei Med J 45 (2004) 847-858
14. Nouso K., Ito Y., Kuwaki K., et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 98 (2008) 1161-1165
15. Yoshikawa M., Saisho H., Ebara M., et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 33 Suppl. (1994) S149-S152
16. Park J.O., Lee S.I., Song S.Y., et al. Measuring response in solid tumours: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33 (2003) 533-537
17. Georgiades C.S., Hong K., D'Angelo M., et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16 (2005) 1653-1659
18. Covey A.M., Maluccio M.A., Schubert J., et al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer 106 (2006) 2181-2189
19. Kim J.H., Yoon H.K., Sung K.B., et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 113 (2008) 1614-1622
20. Cady B. Natural history of primary and secondary tumours of the liver. Semin Oncol 10 (1983) 127-134
21. Lladó L., Virgili J., Figueras J., et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88 (2000) 50-57
22. Konno T. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. Eur J Cancer 28 (1992) 403-409
23. Yumoto Y., Jinno K., Tokuyama K., et al. Hepatocellular carcinoma detected by iodized oil. Radiology 154 (1985) 19-24
24. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 332 (1995) 1256-1261
25. Chung J.W., Park J.H., Han J.K., et al. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 165 (1995) 315-321
26. Chan A.O., Yuen M.F., Hui C.K., et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94 (2002) 1747-1752
27. Shijo H., Okazaki M., Higashihara H., et al. Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization. Am J Gastroenterol 87 (1992) 1154-1159
28. Tarazov P.G., Polysalov V.N., Prozorovskij K.V., et al. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41 (2000) 156-160
29. Kim J.H., Yoon H.K., Kim S.Y., et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 29 (2009) 1291-1298
30. Murata S., Tajima H., Nakazawa K., et al. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. Eur Radiol 19 (2009) 2016-2023